Mechanism of autophagy on radioresistence of head and neck cancer

Research Project

Project/Area Number	18K16902
Research Category	Grant-in-Aid for Early-Career Scientists
Allocation Type	Multi-year Fund
Review Section	Basic Section 56050:Otorhinolaryngology-related
Research Institution	Kyoto Prefectural University of Medicine
Principal Investigator	Arai Akihito 京都府立医科大学, 医学(系)研究科(研究院), 助教 (10716070)
Project Period (FY)	2018-04-01 – 2022-03-31
Project Status	Completed (Fiscal Year 2021)
Budget Amount *help	¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000) Fiscal Year 2021: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000) Fiscal Year 2020: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000) Fiscal Year 2019: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000) Fiscal Year 2018: ¥780,000 (Direct Cost: ¥600,000、Indirect Cost: ¥180,000)
Keywords	p62 / p16陽性中咽頭癌 / 放射線抵抗性 / p62とp16 status / p62と放射線感受性 / 免疫染色 / p16 / 中咽頭癌 / 頭頸部癌におけるp62/SQSTM1の発現
Outline of Final Research Achievements	The relationship between autophagy mechanism and prognosis of head and neck cancer was examined using 30 cases with oropharyngeal cancer. P16 status, and clinical data were also examined. The expression of p62, NrF2κ, surrogate marker of autophagy, was determined by immunohistochemistry. The results indicated no significant correlation between the expression of p62, NrF2κ and any clinical data including p16 status. One possible reason of the negative study may be heterogeneity of the subjects in terms of treatment modality.
Academic Significance and Societal Importance of the Research Achievements	オートファジーと頭頸部癌の治療抵抗性については全く未解明であった。この機構を解明することでオートファジーを標的とした治療法の開発が期待される。